Latest news
25 items- SECSEC Form DEF 14A filed by Renalytix plcDEF 14A - Renalytix plc (0001811115) (Filer)
- PRCommencement of trading on OTCQB in the United StatesLONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB:RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that as previously disclosed regarding its intention to move listing of its American Depository Shares ("ADSs") from Nasdaq to the OTC Markets Group Inc., that effective with the market open today its ADSs are now trading on the OTCQB. The Directors have considered the benefits of the Nasdaq listing against the cost of maintaining the listing and have decided to downlist the ADSs from Nasdaq, and a
- 13D/GAmendment: SEC Form SC 13D/A filed by Renalytix plcSC 13D/A - Renalytix plc (0001811115) (Subject)
- SECSEC Form PRE 14A filed by Renalytix plcPRE 14A - Renalytix plc (0001811115) (Filer)
- SECRenalytix plc filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - Renalytix plc (0001811115) (Filer)
- SECSEC Form 10-K filed by Renalytix plc10-K - Renalytix plc (0001811115) (Filer)
- SECRenalytix plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Renalytix plc (0001811115) (Filer)
- SECRenalytix plc filed SEC Form 8-K: Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Renalytix plc (0001811115) (Filer)
- NEWSHC Wainwright & Co. Reiterates Buy on Renalytix, Maintains $3 Price TargetHC Wainwright & Co. analyst Yi Chen reiterates Renalytix (NASDAQ:RNLX) with a Buy and maintains $3 price target.
- NEWSWhy ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day SessionShares of ASP Isotopes Inc. (NASDAQ:ASPI) fell during Friday's session after the company announced pricing of a $30 million public offering of 12 million shares at $2.50 per share. ASP Isotopes shares fell 9.2% to $3.2308 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Vicinity Motor Corp. (NASDAQ:VEV) shares jumped 133.2% to $0.7910 after the company announced CARB certification for the VMC 1200 class 3 electric truck. Qualigen Therapeutics, Inc. (NASDAQ:QLGN) shares rose 110% to $0.4335. TOYO Co., Ltd (NASDAQ:TOYO) climbed 63.4% to $2.5322. Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN) jumped 58% to $9.52 foll
- NEWSWhy ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day SessionShares of Conagra Brands, Inc. (NYSE:CAG) fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted EPS guidance below estimates. The company reported adjusted earnings per share of 61 cents, beating the analyst consensus estimate of 57 cents. Quarterly revenues of $2.905 billion missed the street view of $2.930 billion, according to data from Benzinga Pro. Conagra Brands shares declined 3.9% to $27.70 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Kazia Therapeutics Limited (NASDAQ:KZIA) shares surged 88.6% to $1.26. Kazia Therapeutics, on Wednesday, announced result
- NEWSNasdaq Dips Over 300 Points; PepsiCo Reports Weak SalesU.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 points on Thursday. The Dow traded up 0.21% to 39,803.00 while the NASDAQ fell 1.81% to 18,310.23. The S&P 500 also fell, dropping, 0.84% to 5,586.74. Check This Out: Top 4 Real Estate Stocks That Could Lead To Your Biggest Gains In Q3 Leading and Lagging SectorsReal estate shares jumped by 2.8% on Thursday. In trading on Thursday, information technology shares fell by 2.7%. Top Headline PepsiCo Inc (NASDAQ:PEP) reported worse-than-expected second-quarter FY24 revenue. The company reported second-quarter sales growth of 0.8% year-on-year to $22.501 billion, missing the analys
- NEWSRenalytix shares are trading higher after the company announced a collaboration with the Steno Diabetes Center, Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease.
- NEWSRenalytix Collaborates With Steno Diabetes Center, Cpenhagen, To Develop A Roadmap For Implementation Of KidneyIntelX, Marking First Expansion For KidneyIntelX Platform Beyond US
- PRRenalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond USLONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno'), Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD). The initial focus of the collaboration will be on developing a roadmap for implementation of KidneyIntelX at the Steno Diabetes Center and affiliated practices. Through this collaboration Renalytix and Steno will in
- SECSEC Form EFFECT filed by Renalytix plcEFFECT - Renalytix plc (0001811115) (Filer)
- SECSEC Form 424B3 filed by Renalytix plc424B3 - Renalytix plc (0001811115) (Filer)
- NEWSRenalytix Fights Nasdaq Delisting with Strategic Plan, Trading Temporarily SafeRenalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the "Panel"), which request has now stayed the suspension of the Company's securities pending the Panel's decision as described below. Throughout the hearings process, pending the Panel's decision, the Company's American Depositary Shares ("ADSs") will continue trading on The Nasdaq Global Market under the symbol "RNLX." At the Panel hearing, the Company intends to present a strategic plan to regain compliance with the applicable Nasdaq listing requirements. However, there can be no assurance that the Company's plan will be accepted by the Panel or that, if it i
- PRRenalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting DeterminationLONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ:RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the "Panel"), which request has now stayed the suspension of the Company's securities pending the Panel's decision as described below. Throughout the hearings process, pending the Panel's decision, the Company's American Depositary Shares ("ADSs") will continue trading on The Nasdaq Global Market under the symbol "RNLX." At the Panel hearing, the Company intends to present a strategic plan to regain compliance with the applicable Nasdaq listing requirements. However, there can be no assurance that the Comp
- SECAmendment: SEC Form S-3/A filed by Renalytix plcS-3/A - Renalytix plc (0001811115) (Filer)
- SECAmendment: Renalytix plc filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K/A - Renalytix plc (0001811115) (Filer)
- SECRenalytix plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Renalytix plc (0001811115) (Filer)
- SECRenalytix plc filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Renalytix plc (0001811115) (Filer)
- SECRenalytix plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Renalytix plc (0001811115) (Filer)
- NEWSRenalytix shares are trading higher after the company announced Medicare issued a final Local Coverage Determination for its kidneyintelX.dkd testing
RNLX FAQ
7 questionsWhat does Renalytix plc do?
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial...Where does RNLX stock trade?
Renalytix plc (RNLX) is listed on NASDAQ.What sector and industry is RNLX in?
Renalytix plc operates in the Health Care sector, Medical Specialities industry.When did Renalytix plc go public?
Renalytix plc (RNLX) completed its IPO in 2020.What are analysts saying about RNLX?
Renalytix plc has had 4 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $3000.00 price target on 2022-01-18. Recent price targets range from $2400.00 to $3800.00.What companies are similar to RNLX?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare RNLX side-by-side with any of them on Quantisnow.How can I track RNLX on Quantisnow?
Quantisnow aggregates Renalytix plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RNLX to receive live email and push alerts on every new disclosure.